Salivary Gland Cancer Clinical Trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For salivary gland cancer patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

  • Below is a list of salivary gland cancer clinical trials that are currently open and accepting patients at SCCA.
  • For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 3 of 3 trials.

Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
View Trial
Investigator:
Christina S. Baik
, MD, MPH
Study ID:
NCT02576431
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
View Trial
Investigator:
Heidi J. Gray
, MD
Study ID:
NCT02834013
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally - Advanced Resected Head and Neck Cancer
View Trial
Investigator:
George E. Laramore
, MD, PhD
Study ID:
NCT00956007